Epidemiological characteristics and molecular basis of fluoroquinolone-resistant Neisseria gonorrhoeae strains isolated in Korea and nearby countries

J Antimicrob Chemother. 2004 Aug;54(2):451-5. doi: 10.1093/jac/dkh345. Epub 2004 Jul 1.

Abstract

Objectives: This study was performed to examine the cause of the increase in quinolone-resistant Neisseria gonorrhoeae (QRNG) observed in Korea.

Methods: The antimicrobial susceptibilities of 190 isolates of gonococci from Korea in 2000 were examined by NCCLS methods, and subsets of these isolates underwent mutation analysis of the quinolone resistance-determining regions (QRDRs) of gyrA and parC. Molecular epidemiological characterization of 25 Korean isolates and 54 isolates from overseas was performed by pulsed-field gel electrophoresis (PFGE) and the results compared.

Results: Most (172, 90.5%) of the 190 gonococci tested displayed reduced susceptibility to ciprofloxacin. All strains with high-level ciprofloxacin resistance (ciprofloxacin MIC >/= 4 mg/L) contained a double amino acid alteration at the 91 and 95 positions in the QRDR of GyrA and a single alteration in ParC. PFGE types of high-level QRNG in Korea were mostly different from those of other nearby countries.

Conclusions: These results suggest that the observed increase in ciprofloxacin-resistant isolates is due to the mutation and spread of Korean multiclonal isolates rather than importation from overseas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Anti-Infective Agents / pharmacology*
  • Ciprofloxacin / pharmacology
  • DNA Gyrase / genetics
  • DNA Mutational Analysis
  • DNA Topoisomerase IV / genetics
  • Electrophoresis, Gel, Pulsed-Field
  • Fluoroquinolones / pharmacology*
  • Gonorrhea / epidemiology*
  • Gonorrhea / microbiology*
  • Humans
  • Korea / epidemiology
  • Microbial Sensitivity Tests
  • Molecular Epidemiology
  • Neisseria gonorrhoeae / drug effects*
  • Neisseria gonorrhoeae / genetics*

Substances

  • Anti-Infective Agents
  • Fluoroquinolones
  • Ciprofloxacin
  • DNA Topoisomerase IV
  • DNA Gyrase